Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.

doi:10.1007/s11033-020-05956-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.

Molecular biology reports - 1 Nov 2020

Dos Santos Erinaldo Ubirajara Damasceno, da Silva Isaura Isabelle Fonseca Gomes, Asano Amdore Guescel C, Asano Nadja Maria Jorge, De Mascena Diniz Maia Maria, de Souza Paulo Roberto Eleutério

Abstract excerpt

Levodopa-induced dyskinesia (LID) is an adverse effect that negatively impacts the quality of life of patients with Parkinson's disease (PD). Studies report that genetic variations in the genes of the pharmacogenetic pathway of the levodopa (L-DOPA) might be associated with LID development. The goal of the present study was to investigate a possible influence of functional genetic variants in the DRD1 (rs4532),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catechol O-Methyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dopamine Plasma Membrane Transport Proteins

Share to Dyskinesias

Share to Kaplan-Meier Estimate

Share to Levodopa

Share to Pharmacogenetics

Share to Receptors, Dopamine D1

Share to Receptors, Dopamine D2

Source

Open in PubMed

Identifiers

PMID: 33151475
DOI: 10.1007/s11033-020-05956-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.PMID 33151475Read ↗

Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease.Semantic proximity Read ↗

Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia.Semantic proximity Read ↗

Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinson's Disease: A Meta-Analysis and Systematic Review.Semantic proximity Read ↗

Dopamine pathway and Parkinson’s risk variants are associated with levodopa-induced dyskinesiaSemantic proximity Read ↗

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.Semantic proximity Read ↗

The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson's disease.Semantic proximity Read ↗

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s diseaseSemantic proximity Read ↗

Parkinson’s Disease Pharmacogenomics: New Findings and PerspectivesSemantic proximity Read ↗

Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.Semantic proximity Read ↗

Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson's disease.Semantic proximity Read ↗

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's DiseaseSemantic proximity Read ↗

Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.